Domestic gene sequencer into the first four generations of products landing will be how to stir the gene sequencing ecology.

Wen: Wang Shiwei has been a long time, the gene sequencer market has been under the monopoly of a few overseas giants.
the second-generation gene sequencer developed by Huada Zhicheng went on sale, the situation took a subtle change, and people began to think about how to choose between imported and domestic gene sequencer.
, the horn of the home-made sequencer counterattack was blown years ago.
this point, from the domestic sequencer gradually differentiated out of technology acquisition, licensing cooperation, independent research and development of three development models can be seen one or two.
However, the brand cooperation of domestic sequencer more services for specific gene testing products, landing very quickly, but the market ceiling is not high, and independent research and development of gene sequencer cycle is relatively long, domestic sequencer developers in a relatively calm environment quietly.
recently, arterial network found Qi carbon technology in its official website line its first product QNome-9604 officially released the news, this is the first of its kind.
Qi carbon technology was established in September 2016, the founding team with protein engineering, fluid chip, electrical signal collection and processing and other interdisciplinary background, they use nano-hole gene sequencing technology, independent development of fast, low-cost, miniaturized fourth-generation gene sequencer and supporting reagents.
understand that QNome-9604 is an important phased achievement of Qi Carbon Technology team's research and development for 4 years, and its function and stability are still in the rapid optimization iteration.
, we will try to analyze the new changes facing the gene sequencing industry from the supply-side perspective of gene sequencer.
domestic breakthrough, ecological construction is the purchaser of hard core play gene sequencer, including scientific research laboratories, independent medical laboratories and medical institutions.
, gene sequencer because of the high price, complex operation, the central third-party inspection is the main landing mode.
statistics, nearly 90% of the domestic market share of genetic testing by more than a dozen large independent medical tests occupied.
, inspired by the prevention and control of the new crown outbreak, many hospitals set out to set up in-house laboratories to serve nucleic acid testing needs, and this part of the hospital next or consider purchasing gene sequencer.
arterial network from the relevant practitioners learned that at this stage of the domestic hospital market stock gene sequencer only about 800 units, and the average annual growth in the number of about 100 units.
the national health care institutions at the end of March 2020, there were 1.009 million medical and health institutions and 34,000 hospitals, according to data disclosed by the National Health and Welfare Commission's Statistical Information Center.
health care facilities clearly constitute the blue sea market that has not yet been developed by gene sequencer manufacturers.
the past 10 years, Berry and Kang, Annoyoda, Panshengzi, Boao Bio and other domestic second-generation gene sequencers have been approved for listing.
but these products have been developed, more of a counter-measure against the repeated cost increases of instrument dealers who have long monopolized the upper reaches of the gene sequencing industry chain.
the core logic they embody is not the domestic gene sequencer' attack, but the strength of the upstream giant.
In 2014, Daan Gene DA Proton was approved to provide information on the human genome, human exon group, or entire transcription group in a matter of hours, faster than other sequencing technologies to fully meet the early, fast, low cost requirements of non-invasion prenatal testing, but this product's technology comes from Life Technologies' authorized local sequencing instrument.
2015, Berry Gene and Illumina were approved for the market.
using edge synthesis edge sequencing-related technologies authorized by illumina, nextSeq CN500 can process 96 NIPT clinical samples at a time while ensuring data accuracy.
2017, NextSeq 550AR, developed in partnership with Annoyoda and Illumina, was approved for listing.
This desktop sequencer is developed, manufactured, applied and registered by Annoyoda in China, but the core technology still uses the two-channel "Side Synthesis Edge Sequencing (SBS)" and the classic "reversible end terminator" patent developed by Illumina.
Thermo Fisher's products, developed in partnership with domestic sequencing service providers, went on sale in 2015 as Bioelectron Seq 4000 of Boao Bio.
, it can be seen that almost all mainstream second-generation gene sequencer manufacturers have partially licensed domestic sequencing service providers for cooperative development.
The aforementioned relevant practitioners told Arterial Network, this label development model is relatively efficient, its weakness is that the labeling party can not obtain the original instrument manufacturer's innovation dividend, resulting in the product in the rapidly upgrading of the technical environment lack of vitality.
Sorgo capital is Qi carbon technology A round lead investor, its project leader told arterial network, in fact, foreign mainstream gene sequencer manufacturers have bid farewell to the "printer and cartridge" traditional sales model, but based on more comprehensive strategic considerations, with the ecological chain partners to carry out in-depth cooperation.
in the view of the project leader, in the case of Illumina, the construction of the ecosystem has spawned three major business models.
first, actively explore new application scenarios, label production can be counted as such scenes of a landing method.
January 2016, Illumina, in association with Bill Gates, Bezos Expeditions and other funds, announced the creation of Grail, which seeks to find a technology or product that enables early cancer screening with simple blood testing skills.
' application for a NASDAQ listing in September 2020 was followed by news that Illumina was planning to buy Grail for $8 billion.
In early 2017, llumina and Bio-Rad jointly released a single-cell genome sequencing solution, the first next-generation sequencing (NGS) workflow for single-cell analysis, enabling researchers to explore the synergies of individual cells in terms of tissue function, progression and therapeutic response.
second, embedded in the hospital consultation process.
For example, in November 2016, Illumina established a bioinficional partnership with Mayo Hospital, which plans to integrate existing services and software and adopt new and innovative solutions to improve the reporting workflow for genetic diseases at Mayo Hospital, where Illumina also develops an information platform and knowledge base to refine and automate the interpretation of genomes.
third, cross-border cooperation.
January 2017, Illumina announced partnerships with Philips and IBM.
the former plans to integrate Illumina's sequencing system into the veteran IntellySpace Genomics clinical information platform and coordinate marketing and sales solutions, while the latter plans to integrate Illumina's BaseSpace with its own Watson for Genomics to standardize and simplify genomic data interpretation during tumor sequencing.
project leader speculated that in the future, the domestic gene sequencer will also adopt the development model of in-depth cooperation with mid-range service providers.
On the one hand, sequencer manufacturers need to communicate repeatedly with mid-range service providers to obtain the demand and direction of product iteration and upgrading, on the other hand, the unique survival logic of the large package is not conducive to the long-term development of gene sequencing enterprises, the construction of ecological circle is a very necessary business path.
fourth generation sequencer landed, just need or mess up? "In the process of gene sequencing service extension and connotation expansion, domestic gene sequencer manufacturers may choose differentiated application scenarios according to the technical characteristics of different intergenerational products.
" for the arterial network proposed three generations, and even four generations of gene sequencer market demand considerations, Sorge capital project leader so explained.
the history of gene sequencing, it is actually a cutting-edge technology has become a new and just-needed history.
first appeared in the scientific research CRO service in 2006, gene sequencing has entered the clinical field quickly and large-scale, providing rich bio-information interpretation data while helping medical testing to achieve leapfrog progress.
, the mainstream gene sequencing technique completed four iterations.
generation sequencing has long reading length and high accuracy, but the low volume and high cost make it difficult to meet the data mass requirements of modern bio-trust analysis model.
2010, illumina developed a second-generation gene sequencer that quickly entered the market with high-volume, high-accuracy technology features and driven a rapid decline in gene sequencing costs.
can be said that the second generation gene sequencer in the gene sequencing from high-sharp scientific research services into clinical applications in the process played an important role.
even so, second-generation gene sequenceres are not omnable.
the length of NGS reading and the difficulty of operation, it is not possible to cover the sequencing needs of complex samples in a wider clinical scenario.
Then, the three- and four-generation sequencing technology based on single-molecule fluorescence sequencing and single-molecule nano-hole sequencing has been developed rapidly, and its characteristics of long reading, flexible and convenient have ignited the industry's new enthusiasm for gene sequencing applications.
Five intergenerational gene sequencer compared to Sorgan Capital project leader pointed out that the use of ultra-long reading length, four generations of gene sequencer can be the pathogen and other organisms accurate sequencing, to avoid fragment stitching introduced errors, "in the pathogen microbial sequencing, due to the subtype of different viruses Or hundreds of bacteria form a mixture, the base fragments are very similar, NGS technology can often only detect a variety of viruses or a variety of bacteria common fragments, so it is difficult to accurately determine the virus or bacterial type, but the long fragments of nano-hole sequencing can be more accurately located pathogen classification.
QNome-9604 uses innovative nano-hole gene sequencing principles to sequence genes based on electrical signals, according to data published on Qi Carbon Technology's official website.
technical indicators, QNome-9604 sequencing 8 hours can produce 500Mbp data, reach the medium-volume level, suitable for microbial detection, amplification sub-sequencing and other fast and flexible use scenarios, detachable chip design reduces the cost of single use.
QNome-9604 sequencer, QNome-9604 accuracy is competitive and reads more than 150k, and reading longer is also a feature of nano-hole gene sequencing technology.
arterial network learned that with the sequencer released together, there is a supporting sequencing chip QCell-3841 and sequencing kit Qeagen-8.
Arterial network approaching practitioners also pointed out that compared to replacing the second generation gene sequencer in the original scene, the more important value of the fourth generation gene sequencer is to make full use of their own more flexible, portable, time-consuming characteristics, to create new gene sequencing scenarios, such as the scientific research work freed from the laboratory, so that rapid visual home gene sequencing is possible.
, we prefer to apply ecological sustained prosperity to current gene sequencing.
and in this ecology, the emergence and growth of domestic brands is undoubtedly a useful thing for the industrial chain, in the middle and downstream.
will continue to pay attention to the market performance of domestic sequencer.
.